更新于：2024-11-01

APL Research Centre Ltd.

子公司|

India

子公司|

India

更新于：2024-11-01

概览

关联

项与 APL Research Centre Ltd. 相关的临床试验

CTRI/2018/09/015741 / Completed临床1期

An, Open-label, Randomized, Three-Treatment, Four-sequence, Two-period, Cross-over, Multiple dose, Steady state Clinical Bioequivalence Study of two different formulations of Cariprazine Capsules 6 mg of Aurobindo Pharma Limited, India (T1 and T2) with VRAYLAR (Cariprazine) Capsules 6mg of Allergan USA, Inc. Irvine, CA 92612, USA(Reference) in patients already receiving a stable dose of Cariprazine capsules 6 mg

开始日期2018-10-19

申办/合作机构

APL Research Centre Ltd.

[+1]

CTRI/2017/12/010926 / CompletedN/A

A Multicentric, Open-label, Randomized, Two Treatment, Two Sequence, Cross Over, Clinical Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (IV) 2 mg/ml (50mg/m2) of Auromedics Pharma LLC, USA (Test) With Doxorubicin Hydrochloride Liposome Injection (IV) 2 mg/ml (50mg/m2) of Sun Pharmaceutical Industries, Inc, USA (Reference) in Ovarian Cancer Patients whose disease has progressed or recurred after platinum-based chemotherapy under fasting conditions - CR150-16

开始日期2018-01-23

申办/合作机构

APL Research Centre Ltd.

CTRI/2018/01/011185 / RecruitingN/A

An open label, randomized, single centre two-treatment, two-sequence, two-period, crossover, multiple dose comparative oral bioavailability study of Nevirapine Prolonged Release Tablets 400 mg (Test) of Aurobindo Pharma Ltd., India and Viramune (Nevirapine) 400 mg Prolonged-Release Tablets (Reference) of Boehringer Ingelheim Pharma GmbH & Co.KG, Germany in 36 HIV-1 Infected Patients under fasting conditions.

开始日期2018-01-20

申办/合作机构

APL Research Centre Ltd.

100 项与 APL Research Centre Ltd. 相关的临床结果

登录后查看更多信息

0 项与 APL Research Centre Ltd. 相关的专利（医药）

登录后查看更多信息

项与 APL Research Centre Ltd. 相关的文献（医药）

2024-02-25·Oriental Journal Of Chemistry

UHPLC Specific Method for Simultaneous Determination of Probable Impurities of Ezetimibeand Simvastatin in Combined Dosage Form

作者: Vittal, Sathapathy Panduranga ; Suryakala, Duvvuri ; Vadivelu, Anantha Lakshmi

Method development, degradation impurities that may appear in Ezetimibe, Simvastatin tablets with Ultra High Performance Liquid Chromatography (UHPLC or UPLC) technique. Water’s Acquity High strength (HSS) T31.8µ, 100x 2.1mm column is used for critical separation between closely eluting impurities originating from the combined dosage form. Perchloric acid buffer (1.0 mL/L)and acetonitrile are selected as Elution phase A, B. The resolution between polar, mid polar and highly polar impurities is achieved with flow of 0.5 mL per minute in step gradient mode with short run time. Detection was done at 238nm for quantification of both Ezetimibe and Simvastatin impurities. Method validation is performed as per compound requirement. The validated UHPLC method is specific and stability demonstrating for process or degradation impurities that may originate from drug product or peaks appears during stress degradation in Ezetimibe and Simvastatin tablets . The method was accurate, robust and validation is as per ICH guide lines. The results are more reliable, precise and reproducible.

2022-07-01·Current Nanomedicine

Pickering Emulsions: A Potential Strategy to Limiting Cancer Development

作者: Joshi, Deshbandhu ; Singh, Shambhavi ; Setia, Aseem ; Baghel, Yudhishthir Singh ; Bhattacharya, Sankha ; Singh, Sushil Kumar

Abstract:Pickering Emulsion therapy is a novel approach to treating various human diseases, in-cluding cancer. Traditional cancer treatment modalities, such as surgery, radiation, radiotherapy, and immunotherapy, have only achieved minimal success. Pickering emulsion in cancer therapeu-tics has given cancer patients a new hope. Pickering Emulsions have grown in popularity over the last 15 years, owing to their highly desirable properties, similar to those of ordinary emulsions, namely their excellent stability. This review focused on the benefits, drawbacks, characterization parameters (droplet size and strength, for example), opportunities, and different development pro-cedures of Pickering Emulsion for cancer diseases. This review also addressed recent developments in Pickering Emulsions' technological issues. It examined the advantages and disadvantages of us-ing such formulations for topical pharmaceutical and cosmetic applications instead of traditional surfactant-based methods. Pickering Emulsion's evolution as a multifunctional dosage form carrier reflects renewed optimism in the pharmaceutical and cosmetic industries.

2021-09-07·Pharmaceutical Sciences

Lipid Polymeric Hybrid Nanoparticles: Formulation Techniques and Effects on Glioblastoma

作者: Baghel, Yudhishtir Singh ; Bhattacharya, Sankha

Introduction: In the pharmaceutical industry, liposomes and polymeric nanoparticles are the two most commonly studied delivery vehicles. A new technique uses lipid-polymeric hybrid nanoparticles (LPHNPs) with a polymeric core, and a shell made up of lipid-lipid-PEG lipids. They have properties which complement polymer nanoparticles and liposomes, and they have the potential to improve the physical stability and biocompatibility of the active pharmaceutical ingredient encapsulated in them. Evaporating the solvent from a dual-phase solution containing lipid and polymer is one of the most effective methods for producing the lipid polymeric hybrid nanoparticles. The LPHNPs applications has also been significantly expanded to include combinational and active targeted drug delivery, as well as delivery of genetic materials, vaccines, and diagnostic imaging agents, in addition to single drug delivery for anticancer therapy, like Glioblastoma. Main goal: The main agenda of this compilation was to address the effects of LPHNPs on Glioblastoma treatment. This compilation also highlights some of the formulation techniques and issues that arise during the preparation of LPHNPs. This review also discusses recent developments in core-shell lipid-polymer hybrid nanoparticles, which were conferred in considerable detail later in this article. Conclusion: The main issue which arises while using nanoparticles with polymer is entrapment efficiency. Because of their hybrid components, LPHNPs have proven to solve this problem to a large extent. The recent research trends suggest that lipid polymeric hybrid nanoparticles will prove to be highly effective or productive in treating diseases such as Glioblastoma.

100 项与 APL Research Centre Ltd. 相关的药物交易

登录后查看更多信息

100 项与 APL Research Centre Ltd. 相关的转化医学

登录后查看更多信息